# US 2025/0155448 A1 · Identification and quantitation of insulin-like growth factor-i variants by mass spectrometry

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0155448 A1
- Document ID: US20250155448A1
- Status: Published application
- Kind: A1
- Application number: 19/008,245
- Filed: 2025-01-02
- Published: 2025-05-15
- Earliest claimed: 2021-03-19
- Assignees: Quest Diagnostics Investments Incorporated
- Applicants: Quest Diagnostics Investments LLC
- Inventors: Ievgen Motorykin; Nigel Clarke; Michael J. McPhaul; Zengru Wu
- Web page: https://patentgrep.com/patent/US20250155448A1

## CPC

- G01N 33/6848: {Methods of protein analysis involving mass spectrometry}
- G01N 33/74: involving hormones {or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors}
- G01N 2333/65: Insulin-like growth factors (Somatomedins), e.g. IGF-1, IGF-2
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)

## Abstract

A method for detecting insulin-like growth factor-I (IGF-I) variant(s) in a sample includes purifying the sample using solid phase extraction, ionizing IGF-I in the purified sample to produce one or more ions detectable by mass spectrometry, detecting one or more of the ions comprising an ion with a mass-to-charge ratio selected from the group consisting of 1093.5±0.5, 1089.8±0.5, 1095±0.5, 1097.09±0.5, and 1098.09±0.5 by mass spectrometry, and using the detected ion or ions to determine the presence of IGF-I variant(s) in the sample.

## Claims

### Claim 1

A method for detecting insulin-like growth factor-I (IGF-I) variant(s) in a sample, the method comprising:
purifying the sample using solid phase extraction;
ionizing IGF-I in the purified sample to produce one or more ions detectable by mass spectrometry;
detecting one or more of the ions comprising an ion with a mass-to-charge ratio selected from the group consisting of 1093.5±0.5, 1089.8±0.5, 1095±0.5, 1097.09±0.5, and 1098.09±0.5 by mass spectrometry; and
using the detected ion or ions to determine the presence of IGF-I variant(s) in the sample.

### Claim 2 (depends on 1)

The method of claim 1, wherein the detection of m/z 1089.8±0.5 determines the presence of P66A4, R55K6, or R36Q6.

### Claim 3 (depends on 1)

The method of claim 1, wherein the detection of m/z 1095±0.5 determines the presence of A67S4 or T29I8.

### Claim 4 (depends on 1)

The method of claim 1, wherein the detection of m/z 1097.09±0.5 determines the presence of S34N2, A70P3, A38V1, M59R4, or A67S13.

### Claim 5 (depends on 1)

The method of claim 1, wherein the detection of m/z 1098.09±0.5 determines the presence of S34N9, A70P10, A38V8, M59R11, V17/44M4, R50W6, T4M6, or A67/70T6.

### Claim 6 (depends on 1)

The method of claim 1, wherein the mass spectrometry is performed with a Q Exactive Focus Hybrid Quadrupole-Orbitrap instrument.

### Claim 7 (depends on 1)

The method of claim 1, wherein the sample comprises plasma or serum.
